FACS analysis of bone marrow cells from WT and TAC4−/− mice cultured in the presence of IL-7 for 4 days
Population . | B-cell stage . | Fraction . | WT . | TAC4−/− . | P . |
---|---|---|---|---|---|
Total cell number | 5.6 ± 0.9 × 106 | 8.2 ± 1.2 × 106 | .0647 | ||
B220+CD117+ | Unc → pro-B | A → C | 1.7 ± 0.4 × 106 | 3.4 ± 0.7 × 106 | .0216* |
B220+CD117− | pre-B → mat | C′ → mat | 2.5 ± 0.4 × 106 | 2.8 ± 0.5 × 106 | .5899 |
CD2−CD117+ | ELP → pro-B | ELP → C | 1.1 ± 0.3 × 106 | 2.4 ± 0.5 × 106 | .0127* |
CD2−CD117− | pre-B | C′ | 0.7 ± 0.2 × 106 | 1.1 ± 0.2 × 106 | .0729 |
CD2+CD117− | pre-B → mat | D → mat | 2.6 ± 0.5 × 106 | 2.9 ± 0.6 × 106 | .6453 |
CD19+CD2−IgM− | pro-B → pre-B | B → C′ | 1.7 ± 0.4 × 106 | 3.4 ± 0.6 × 106 | .0124* |
CD19+CD2+IgM− | pre-B | D | 1.9 ± 0.3 × 106 | 2.0 ± 0.4 × 106 | .8244 |
CD19+CD2+IgM+ | imm → mat | E → mat | 0.7 ± 0.1 × 106 | 1.1 ± 0.2 × 106 | .0969 |
CD19+CD2−IL7Rα+ | pro-B → pre-B | B → C′ | 1.8 ± 0.4 × 106 | 3.6 ± 0.6 × 106 | .0134* |
CD19+CD2+IL7Rα+ | pre-B → imm | D,E | 1.7 ± 0.3 × 106 | 1.9 ± 0.4 × 106 | .6064 |
CD19+CD2+IL7Rα− | imm → mat | imm → mat | 0.7 ± 0.2 × 106 | 0.7 ± 0.2 × 106 | .7970 |
CD19+IgM−IgD− | pro-B → pre-B | B → D | 3.3 ± 0.6 × 106 | 5.3 ± 0.8 × 106 | .0495* |
CD19+IgM+IgD− | imm | E | 0.7 ± 0.1 × 106 | 0.9 ± 0.2 × 106 | .2613 |
CD19+IgM+IgD+ | imm → mat | imm → mat | 0.3 ± 0.1 × 106 | 0.4 ± 0.1 × 106 | .0718 |
Population . | B-cell stage . | Fraction . | WT . | TAC4−/− . | P . |
---|---|---|---|---|---|
Total cell number | 5.6 ± 0.9 × 106 | 8.2 ± 1.2 × 106 | .0647 | ||
B220+CD117+ | Unc → pro-B | A → C | 1.7 ± 0.4 × 106 | 3.4 ± 0.7 × 106 | .0216* |
B220+CD117− | pre-B → mat | C′ → mat | 2.5 ± 0.4 × 106 | 2.8 ± 0.5 × 106 | .5899 |
CD2−CD117+ | ELP → pro-B | ELP → C | 1.1 ± 0.3 × 106 | 2.4 ± 0.5 × 106 | .0127* |
CD2−CD117− | pre-B | C′ | 0.7 ± 0.2 × 106 | 1.1 ± 0.2 × 106 | .0729 |
CD2+CD117− | pre-B → mat | D → mat | 2.6 ± 0.5 × 106 | 2.9 ± 0.6 × 106 | .6453 |
CD19+CD2−IgM− | pro-B → pre-B | B → C′ | 1.7 ± 0.4 × 106 | 3.4 ± 0.6 × 106 | .0124* |
CD19+CD2+IgM− | pre-B | D | 1.9 ± 0.3 × 106 | 2.0 ± 0.4 × 106 | .8244 |
CD19+CD2+IgM+ | imm → mat | E → mat | 0.7 ± 0.1 × 106 | 1.1 ± 0.2 × 106 | .0969 |
CD19+CD2−IL7Rα+ | pro-B → pre-B | B → C′ | 1.8 ± 0.4 × 106 | 3.6 ± 0.6 × 106 | .0134* |
CD19+CD2+IL7Rα+ | pre-B → imm | D,E | 1.7 ± 0.3 × 106 | 1.9 ± 0.4 × 106 | .6064 |
CD19+CD2+IL7Rα− | imm → mat | imm → mat | 0.7 ± 0.2 × 106 | 0.7 ± 0.2 × 106 | .7970 |
CD19+IgM−IgD− | pro-B → pre-B | B → D | 3.3 ± 0.6 × 106 | 5.3 ± 0.8 × 106 | .0495* |
CD19+IgM+IgD− | imm | E | 0.7 ± 0.1 × 106 | 0.9 ± 0.2 × 106 | .2613 |
CD19+IgM+IgD+ | imm → mat | imm → mat | 0.3 ± 0.1 × 106 | 0.4 ± 0.1 × 106 | .0718 |
Columns WT and TAC4−/− show absolute cell numbers (mean ± SE, n = 10). Surface markers used for FACS analysis and the developmental stage of B-cell populations are indicated: ELP (early lymphoid progenitor), fractions A (uncommitted [unc]), B and C (pro-B), C′ and D (pre-B), E (immature [imm] and mature [mat]). P values were calculated from absolute cell numbers using paired 2-tailed t tests.
Significance (P < .05).